Soluble HLA class I antigens in plasma of patients with malignant melanoma.
The high mortality rate of melanoma patients who develop metastases prompted us to look for prognostic markers to determine high-risk and non-risk patients at the primary tumour stage. Therefore, we quantified plasma concentrations of soluble HLA class I antigens (sHLA-I) by ELISA in patients with primary tumours (MM-P) and with metastases (MM-M), respectively, and compared them to a control group. Whereas healthy probands (n = 55) and MM-M (n = 38) showed similar mean values of sHLA-I (1.30 +/- 1.44 micrograms/ml and 1.29 +/- 1.27 micrograms/ml), MM-P (n = 67) revealed significantly reduced levels of this marker (0.84 +/- 0.85 microgram/ml). This result matches with our immunohistological staining of membrane-bound HLA-I in sections of paraffin-embedded melanoma. Further subdivision of the MM-P substantiated the observation that mean values of decreased sHLA-I concentrations are in line with high tumour thickness. Since the beginning of this study (1990) to date, 11 of 67 MM-P have developed metastases. The prognostic efficiency of sHLA-I to identify high-risk and non-risk patients was tested by ROC-analysis (receiver operating characteristic) and did not demonstrate good prognostic relevance for sHLA-I (W = 0.64, p = 0.04).
Westhoff
U
U
Department of Tumour Research, Fachklinik Hornheide, Münster, Germany.
Fox
C
C
Otto
F J
FJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D018450:Disease Progression; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000097:blood* / Q000276:immunology; D006801:Humans; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis
D014408:Biomarkers, Tumor; D015395:Histocompatibility Antigens Class I